Research programme: Cancer - Nova Therapeutics/VRise Therapeutics
Latest Information Update: 09 Jan 2023
At a glance
- Originator Nova Therapeutics
- Developer Nova Therapeutics; VRise Therapeutics
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer; Solid tumours
Most Recent Events
- 27 Dec 2022 Nova therapeutics plans IND submission for metastatic cancer in second half of 2022 (Nova therapeutics pipeline, December 2022)
- 27 Dec 2022 Early research in Cancer in Canada (unspecified route) (Nova therapeutics pipeline, December 2022)
- 27 Dec 2022 Early research in Solid tumours in Canada (unspecified route) (Nova therapeutics pipeline, December 2022)